뉴로핏 (Neurophet)

뉴로핏 (Neurophet)

Global pioneer to lead diagnosis and treatment of brain disorders, Neurophet —— 뇌질환 진단과 치료를 선도하는 글로벌 리딩 컴퍼니, 뉴로핏

Founded 2016

Korea South 65 employees Series C Total: $48.00B AI, Machine Learning

Neurophet is a South Korean startup, founded in 2016, focused on harnessing cutting-edge artificial intelligence (AI) technology to develop solutions for brain disorders. Led by CEO Jake Junkil Been and CTO Donghyeon Kim, the company's flagship products include the brain MRI imaging analysis software Neurophet AQUA, the PET scan analysis software Neurophet SCALE PET, and other innovative tools such as Neurophet tES/TMS Lab and Neurophet SegPlus for research purposes. In November 2023, Neurophet successfully secured a KRW20.00B Series C investment from a consortium of investors including the Industrial Bank of Korea, Mirae Asset Securities, DB Financial Investment, Quad Asset Management, Prophet Asset Management, KB Securities, Kolon Investment, Solidus Investment, Xoloninvest, and Seoil & M. The company's mission revolves around providing diagnosis support, treatment guidance, and therapeutic devices for individuals afflicted by brain diseases. By leveraging its deep expertise in neuroscience, Neurophet is committed to utilizing AI technology to advance research, diagnosis, and treatment in the field of neurology. With a strong emphasis on addressing critical brain health issues, Neurophet aims to pave the way for innovative solutions in the realm of brain disorders.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	KRW20.00B	10	Industrial Bank of Korea, Mirae Asset Securities +8	07 Nov 2023
Series B	KRW19.00B	6	FuturePlay, SBI Investment +4	09 Nov 2021
Series A	KRW3.00B	1	SBI Investment Korea	02 Feb 2020
Series A	KRW6.00B	7	Daedeok Venture Partners, Magellan Technology Investment +5	02 Dec 2019
Non Equity Assistance	Undisclosed	1	TIPS Program	01 Nov 2016
Pre Seed Round	Undisclosed	1	FuturePlay	10 Mar 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

KRW20.00B

Industrial Bank of Korea, Mirae Asset Securities +8

07 Nov 2023

Series B

KRW19.00B

FuturePlay, SBI Investment +4

09 Nov 2021

Series A

KRW3.00B

SBI Investment Korea

02 Feb 2020

Series A

KRW6.00B

Daedeok Venture Partners, Magellan Technology Investment +5

02 Dec 2019

Non Equity Assistance

Undisclosed

TIPS Program

01 Nov 2016

Pre Seed Round

Undisclosed

FuturePlay

10 Mar 2016

FAQ About 뉴로핏 (Neurophet)

Global pioneer to lead diagnosis and treatment of brain disorders, Neurophet —— 뇌질환 진단과 치료를 선도하는 글로벌 리딩 컴퍼니, 뉴로핏

뉴로핏 (Neurophet) was founded in 2016.

뉴로핏 (Neurophet) is headquartered in Korea South.

뉴로핏 (Neurophet) operates in AI and Machine Learning. Its work centres on Neuroscience, Neuroimaging, Medical imaging and Neuroradiology.

뉴로핏 (Neurophet) has approximately 65 employees.

뉴로핏 (Neurophet) has completed 6 funding rounds, raising a total of $48.00B. The latest funding stage is Series C.

Top alternatives and competitors to 뉴로핏 (Neurophet) include Machine Medicine, Deep01 Technology, Hypervision Surgical, Skintelligent, Altris AI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

뉴로핏 (Neurophet) and Machine Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About 뉴로핏 (Neurophet)

Funding Rounds & Investors (6)

뉴로핏 (Neurophet) Alternatives & Competitors

FAQ About 뉴로핏 (Neurophet)